Today's Trend
Ascendis Pharma A/S (NASDAQ: ASND) shares have recently decreased despite a favorable new analyst view from HC Wainwright.
- HC Wainwright initiated coverage of Ascendis Pharma with a Buy rating and a $345 price target, implying approximately 39% potential upside from the referenced share price. The bullish stance provides positive analyst support for ASND. HC Wainwright initiates coverage
- HC Wainwright analyst M. Kapoor projected Ascendis Pharma will earn $3.93 per share in fiscal 2026, broadly above the cited consensus estimate of $3.90, and expects quarterly EPS of $1.16 in Q3 2026 and $1.66 in Q4 2026. HC Wainwright FY2026 estimates
- The firm forecast substantial earnings growth in 2027, with quarterly EPS estimates rising from $1.76 in Q1 to $4.42 in Q4, resulting in projected full-year EPS of $11.88. If achieved, that would represent a significant improvement over the 2026 forecast and supports the analyst’s optimistic valuation. HC Wainwright FY2027 estimates
The news is favorable for ASND because it adds bullish sell-side coverage and highlights expectations for accelerating profitability. However, the estimates are forward-looking, and the stock’s recent decline suggests investors may be awaiting additional operating or clinical catalysts before fully responding to the analyst outlook.